790.00 DA

01 FC:1801



PTO/SB/30 (04-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to	respond to a collection of information	on unless it display	s a valid OMB control number.					
Request For	Application Number	10/052,386-Conf. #5995						
Continued Examination (RCE)	Filing Date	January 18, 2002						
Transmittal	First Named Inventor	Anil Saksena						
Address to: MS RCE	Art Unit	1653						
Commissioner for Patents P.O. Box 1450	Examiner Name	R. B. Mondesi						
Alexandria, VA 22313-1450	Attorney Docket Number	SCHERING	G 3.0-122 CIP					
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.								
Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action								
may be considered as a submission even if this box is not checked.								
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on								
ii. Other								
b. X Enclosed i. X Amendment/Reply iii. X Information Disclosure Statement (IDS)								
Copy of European Search Report								
ii. Affidavit(s)/Declaration(s) iv. Other Copies of cited references								
2. Miscellaneous								
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a								
period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)								
b. Other The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.								
a. The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments to Deposit Account No. 12-1095 . I have enclosed a duplicate copy of this sheet.								
i. X RCE fee required under 37 CFR 1.17(e)								
ii. Extension of time fee (37 CFR 1.136 and 1.17)								
iii. Other								
b. Check in the amount of \$ enclosed								
c. Payment by credit card (Form PTO-2038 enclosed)								
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED								
Signature QUARTER CO.	Date	May 19, 20	05					
Name (Print/Type) Harvey L. Cohen	Registra	•	3,365					
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Bero1450, Alexandria, VA 22313-1450, on the date shown below. Dated: May 19, 2005 Signature: (Harvey L. Cohen)								

PE CIES

AMENDMENT TRANSMITTAL LETTER

Docket No. SCHERING 3.0-122

Application No. Filing Date Examiner Art Unit 10/052,386-Conf. #5995 January 18, 2002 R. B. Mondesi 1653

Applicant(s): Anil Saksena

Invention: NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

		CLAIM	S AS AMENI	DED		
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present		Rate	
Total Claims	78	- 128 =		х		
Independent Claims	6	- 15 =		х	<u>.</u>	
Multiple Depend	dent Claims (ch	eck if applicabl	e)			
Other fee (pleas	se specify):					
TOTAL ADDIT	IONAL FEE FO	OR THIS AME	NDMENT:	71.10		0.00
x Large Entity					Small Entit	ry .
	al fee is require	d for this amer	ndment.		•	
A duplicate	ge Deposit Acc	eet is enclosed				
A check in tl	ne amount of \$		to cover	the fili	ng fee is en	closed.
Payment by	credit card. Fo	orm PTO-2038	is attached.			
X The Director	r is hereby auth d below. A dup	orized to char	ge and credit this sheet is e	Depo	sit Account ed.	No. <u>12-1095</u>
x Credit a	ny overpaymer	nt.				
× Charge	any additional fil	ing or applicatio	n processing	fees re	quired unde	r 37 CFR 1.16 and 1.17.
Have					Dated:	May 19, 2005
Harvey L. Cohe Attorney Reg. I	en 🔨					
LERNER, DAV 600 South Ave Westfield, New (908) 518-6425	nue West Jersey 07090		LZ & MENTL	IK, LL	Þ	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P. Box 1450, Alexandria, VA 22313-1450, on the date shown

below.

Dated: May 19, 2005

Signatures

(Harvey L. Cohen)

PE COMMAN 2 3 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria XA 22313-X450, on the date shown below.

ated: May 19, 2005

Signature:

Docket No.: SCHERING 3.0-122 CIP (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Anil Saksena

Application No.: 10/052,386

: Group Art Unit: 1653

Filed: January 18, 2002

: Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE

PROTEASE INHIBITORS OF

HEPATITIS C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT IN CONNECTION WITH REQUEST FOR CONTINUED EXAMINATION

Dear Sir:

In connection with a Request for Continued Examination, Applicants submit the following amendments and remarks. Furthermore, an Information Disclosure Statement has been filed contemporaneously herewith.